BERKELEY, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hypertension) has ...

Cochair of the study, Dr Kim Fox (Royal Brompton Hospital, London), said: "The results of EUROPA represent a milestone in cardiology, proving for the first time the life-saving benefits of an ACE ...

Hydrocodone painkillers face increased federal restriction Perindopril arginine and amlodipine besylate may be used as initial therapy if a patient is likely to need multiple drugs to achieve their ...

Symplmed announced the launch of Prestalia (perindopril arginine, amlodipine) tablets for the treatment of hypertension in patients whose blood pressure is not adequately controlled on monotherapy, ...

Continuing a trend in secondary prevention, the FDA has approved perindopril for the treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality and ...

This community-based trial was undertaken to determine the effectiveness and safety of perindopril in real-life practice settings with hypertensive patients from various demographic subpopulations.

CINCINNATI--(BUSINESS WIRE)--Symplmed Pharmaceuticals announced today that two patents covering Prestalia® (perindopril arginine and amlodipine besylate) are now listed in the U.S. Food and Drug ...

(Reuters) - Xoma Corp said its experimental combination of two drugs met the main goal of lowering hypertension better than a treatment based on either of the drugs alone in a late-stage study, ...

Symplmed announced that the Food and Drug Administration (FDA) has approved Prestalia (perindopril arginine and amlodipine) tablets for the treatment of hypertension in patients whose blood pressure ...